Mechanisms Overview describes a key molecular or cellular mechanism implicated in neurodegenerative disease. This page provides a detailed overview of the pathway components, signaling cascades, and their relevance to conditions such as Alzheimer's disease, Parkinson's disease, and related disorders.
This section covers the molecular and cellular mechanisms underlying neurodegenerative diseases. Understanding these mechanisms is essential for developing disease-modifying therapies and identifying novel therapeutic targets.[1]
The accumulation of misfolded proteins is a hallmark of neurodegenerative diseases, though the causal relationships remain active areas of research.[2]
Cells employ multiple quality control mechanisms to maintain proteostasis, and failure of these systems contributes to neurodegeneration.[8]
Chronic neuroinflammation is a consistent feature of neurodegenerative diseases, though its role as a cause versus consequence remains debated.[10]
Synaptic loss correlates best with cognitive impairment in Alzheimer's disease and is a primary contributor to neuronal network dysfunction.[15]
Genetic discoveries have illuminated mechanistic pathways and identified potential therapeutic targets.[20]
The predominant hypotheses include amyloid-beta accumulation, tau pathology propagation, neuroinflammation, and synaptic loss. Current evidence suggests these processes interact in complex feedforward loops.[24]
Alpha-synuclein aggregation, mitochondrial complex I deficiency, neuroinflammation, and lysosomal dysfunction form the core pathological mechanisms. The relationship between Lewy body formation and neuronal death remains incompletely understood.[25]
TDP-43 aggregation, mitochondrial dysfunction, excitotoxicity, RNA processing defects, and neuroinflammation characterize ALS. Approximately 20% of cases are caused by known genetic mutations.[26]
TDP-43 pathology (most cases), tau pathology (Pick's disease), and FUS pathology represent the major proteinopathies. Behavioural variant FTD and primary progressive aphasia are the main clinical syndromes.[27]
The mechanisms of neurodegeneration are highly interconnected, forming a complex network where multiple pathways influence each other:
This network perspective suggests that combination therapies targeting multiple mechanisms may be more effective than single-target approaches.[28]
Understanding mechanisms enables rational drug design:
GPR3 in neuro-metabolic-immune-reproductive nexus - a potential therapeutic target for Multi-System diseases. ↩︎
'TRPV1 from the TRP family: Structure, function, implication in autoimmune diseases and potential therapies'. ↩︎
'Hydrogen sulfide in precision medicine: connecting basic science, sensing, and clinical application'. ↩︎
'Exosomes for brain drug delivery: The cutting edge in nanomedicine'. ↩︎
Balch WE, et al. Adapting proteostasis for disease intervention. Science. 2008. ↩︎ ↩︎
Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature. 2006. ↩︎ ↩︎
Uttara B, et al. Oxidative stress and neurodegenerative diseases. Current Alzheimer Research. 2009. ↩︎ ↩︎
Hetz C, Saxena S. ER stress and the unfolded protein response in neurodegeneration. Nature Reviews Neurology. 2017. ↩︎ ↩︎
Heneka MT, et al. Neuroinflammation in Alzheimer's disease. The Lancet Neurology. 2015. ↩︎
Salter MW, Stevens B. Microglia emerge as central players in brain disease. Nature Medicine. 2017. ↩︎
Heneka MT, et al. NLRP3 is activated in Alzheimer's disease. Nature Medicine. 2013. ↩︎
Escott C, et al. Astrocyte responses in neurodegeneration. Nature Reviews Neuroscience. 2020. ↩︎
Stephan AH, et al. 'The complement system: an unexpected role in synaptic pruning'. Neuron. 2012. ↩︎
Selkoe DJ. Alzheimer's disease is a synaptic failure. Science. 2002. ↩︎
Kandel ER. 'The molecular biology of memory: cAMP, PKA, CRE, CREB-1, CREB-2, and CPEB'. Molecular Brain. 2012. ↩︎
Lau A, Tymianski M. Glutamate receptors, neurotoxicity and neurodegeneration. Pflügers Archiv - European Journal of Physiology. 2010. ↩︎
Paolicelli RC, et al. Synaptic pruning by microglia is necessary for normal brain development. Science. 2011. ↩︎
Berridge MJ. Calcium hypothesis of Alzheimer's disease. Pflügers Archiv - European Journal of Physiology. 2010. ↩︎
Bekris LM, et al. Genetics of Alzheimer disease. Journal of Geriatric Psychiatry and Neurology. 2010. ↩︎
Coppedè F. The role of epigenetics in neurodegeneration. Journal of Alzheimer's Disease. 2014. ↩︎
Ling SC, et al. RNA metabolism in ALS. Neuron. 2013. ↩︎
Madabhushi R, et al. DNA repair in neuron disease. Neuron. 2014. ↩︎
De Strooper B, Karran E. The cellular phase of Alzheimer's disease. Cell. 2016. ↩︎
Kalia LV, Lang AE. Parkinson's disease. The Lancet. 2015. ↩︎
Taylor JP, Brown RH Jr, Cleveland DW. 'Decoding ALS: from genes to mechanism'. Nature. 2016. ↩︎
Rascovsky K, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011. ↩︎
Gammon K. 'Neurodegenerative disease: brain windfall'. Nature. 2014. ↩︎
Cummings J, et al. 'Alzheimer''s disease drug development pipeline: 2023'. Alzheimer's & Dementia. 2023. ↩︎